Addex Therapeutics Statistics
Total Valuation
ADXN has a market cap or net worth of $12.11 million. The enterprise value is $10.34 million.
| Market Cap | 12.11M |
| Enterprise Value | 10.34M |
Important Dates
The last earnings date was Thursday, June 6, 2024, before market open.
| Earnings Date | Jun 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ADXN has 1.54 million shares outstanding.
| Shares Outstanding | 1.54M |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 3.41% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.72 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.71
| Current Ratio | 0.71 |
| Quick Ratio | 0.38 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -35.48 |
Financial Efficiency
Return on equity (ROE) is -456.60%.
| Return on Equity (ROE) | -456.60% |
| Return on Assets (ROA) | -194.40% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $68,178 |
| Profits Per Employee | -$555,148 |
| Employee Count | 23 |
| Asset Turnover | 0.24 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.39% in the last 52 weeks. The beta is 1.87, so ADXN's price volatility has been higher than the market average.
| Beta (5Y) | 1.87 |
| 52-Week Price Change | -32.39% |
| 50-Day Moving Average | 9.43 |
| 200-Day Moving Average | 9.33 |
| Relative Strength Index (RSI) | 37.53 |
| Average Volume (20 Days) | 3,588 |
Short Selling Information
| Short Interest | 4,678 |
| Short Previous Month | 6,523 |
| Short % of Shares Out | 0.05% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.04 |
Income Statement
In the last 12 months, ADXN had revenue of $1.57 million and -$12.77 million in losses. Loss per share was -$0.14.
| Revenue | 1.57M |
| Gross Profit | 1.53M |
| Operating Income | -9.59M |
| Pretax Income | -12.43M |
| Net Income | -12.77M |
| EBITDA | -11.76M |
| EBIT | -12.09M |
| Loss Per Share | -$0.14 |
Balance Sheet
The company has $1.80 million in cash and $38,932 in debt, giving a net cash position of $1.76 million or $1.14 per share.
| Cash & Cash Equivalents | 1.80M |
| Total Debt | 38,932 |
| Net Cash | 1.76M |
| Net Cash Per Share | $1.14 |
| Equity (Book Value) | -1.52M |
| Book Value Per Share | -0.98 |
| Working Capital | -1.50M |
Cash Flow
In the last 12 months, operating cash flow was -$8.66 million and capital expenditures -$4,839, giving a free cash flow of -$8.67 million.
| Operating Cash Flow | -8.66M |
| Capital Expenditures | -4,839 |
| Free Cash Flow | -8.67M |
| FCF Per Share | -$13.88 |
Margins
Gross margin is 97.37%, with operating and profit margins of -611.76% and -814.26%.
| Gross Margin | 97.37% |
| Operating Margin | -611.76% |
| Pretax Margin | -792.84% |
| Profit Margin | -814.26% |
| EBITDA Margin | -749.90% |
| EBIT Margin | -771.11% |
| FCF Margin | -552.62% |
Dividends & Yields
ADXN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.49% |
| Shareholder Yield | -25.49% |
| Earnings Yield | -105.47% |
| FCF Yield | -71.58% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on October 23, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Oct 23, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
ADXN has an Altman Z-Score of -162.03 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -162.03 |
| Piotroski F-Score | 4 |